1823 results about "Nephrosis" patented technology

The invention relates to the technical field of medical health big data analysis, in particular to a diabetic nephropathy risk identification method and system based on big data analysis, and the method comprises the following steps: screening key index features of risk patients through big data analysis based on health risk data of diabetic nephropathy patients; association of key indexes of the risk patients is analyzed, risk index interaction features are extracted, risk feature constraint conditions are determined, virtual sample parameters are identified through multi-dimensional data association, and a virtual sample set of the risk patients is established. According to the method, interaction characteristic values are extracted by analyzing key indexes of risk patients, high-risk index association is accurately captured, coverage and balance are enhanced based on multi-dimensional data association, non-stationary influence is solved by combining time sequence key change rate and shear point identification, and accurate matching is realized by analyzing offset rate and change trend. And the overall risk level is quantitatively evaluated by integrating interval data weighting, so that the risk identification comprehensiveness and the result reliability are improved.

Aspects of the application provide hemojuvelin antagonists and methods of using the same in treating anemias of kidney disease and conditions associated with these anemias. Methods provided in the application relate to treatment of a subject having an anemia associated with chronic kidney disease and / or kidney disease in a subject that has a level of glomerular filtration rate lower than one or more thresholds.

The invention discloses a peritoneal dialysis anti-blocking high-circulation nursing device for pediatric nephropathy patients, and belongs to the technical field of medical nursing. Comprising the following modules: a multi-mode sensing module for collecting pressure, flow velocity, turbidity, vibration spectrum and temperature data in a catheter in real time; the signal optimization processing module highlights weak features of potential blockage and improves data quality; the feature fusion analysis module is used for comprehensively evaluating the state of the catheter; the AI prediction analysis module is used for predicting the occurrence probability, the position and the possible time window of blockage; the risk early warning and intervention module is used for sending out graded early warning signals according to the prediction result and generating personalized anti-blocking intervention suggestions; the micro-fluidic execution module inhibits formation of initial sediments through a micro-pulse technology and dynamic fluid mechanics adjustment, and effectively reduces the risk of blockage; and the remote medical support module provides visual data visualization and intervention suggestions, supports remote monitoring and emergency intervention, and is seamlessly integrated with a hospital system while ensuring data security.

The invention relates to substituted pyrazolo piperidine carboxylic acids, their salts and to processes for their preparation, and also to their use for preparing medicaments for the treatment and / or prophylaxis of diseases, in particular cardiovascular and cardiac diseases, preferably heart failure with reduced and preserved ejection fraction (HFrEF, HFmrEF and HFpEF), hypertension (HTN), peripheral arterial diseases (PAD, PAOD), cardio-renal and kidney diseases, preferably chronic and diabetic kidney disease (CKD and DKD), cardiopulmonary and lung diseases, preferable pulmonary hypertension (PH), and other diseases, preferably neurodegenerative diseases and different forms of dementias, fibrotic diseases, systemic sclerosis (SSc), sickle cell disease (SCD), wound healing disorders such as diabetic foot ulcer (DFU).

The invention relates to the field of medical information processing and traditional Chinese medicine curative effect evaluation, in particular to a diabetic nephropathy traditional Chinese medicine curative effect evaluation method based on patient report outcome. The method comprises the following steps: searching related symptoms and clinical characterization data of diabetic nephropathy through a medical database, extracting target entries, performing language standardization processing, constructing an initial candidate entry set, calculating the occurrence frequency of each symptom entry, and screening entries meeting a set threshold value to form an entry set; carrying out dimension division on the entry set according to feature attributes to form a preliminary dimension structure set; forming a screening result set through preset logic screening conditions; and carrying out weighted regression fusion on the comprehensive curative effect score and clinical detection data, and outputting a patient curative effect index. In an item weight determination process, dynamic balance between subjective experience and objective statistical information is realized through a mixed weighting model, and the defects of strong subjectivity of expert scoring and large result fluctuation in a traditional method are overcome.

Disclosed are naphthyl compounds comprising either a ureido piperidine-1 -carboxamide or a ureido piperidine-1 -carboxylate moiety, compositions thereof, and methods of use thereof, for treating or preventing a disease or disorder associated with abnormal levels of amino acids by modulation of SLC6A19 transport, such as phenylketonuria, hyperphenylalaninemia, diabetes and chronic kidney disease.

A class of compounds and the use thereof in a drug. Specifically, the present invention relates to a class of new compounds, a pharmaceutical composition containing the compounds, a method for preparing the compounds, and the use of the compounds or the pharmaceutical composition in the preparation of a drug for treating GLP-1 receptor agonist-mediated diseases and / or disorders, particularly the use in the preparation of a drug for treating diabetes, non-alcoholic fatty liver disease, obesity, myocardial infarction, heart failure, diabetic nephropathy, Parkinson's disease and Alzheimer's disease.

The invention relates to an anti-phospholipase A2 receptor polyclonal antibody as well as a preparation method and application thereof. The preparation method comprises the following steps: immunizing animals by taking phospholipase A2 receptor protein as an antigen, and collecting serum; carrying out antibody separation and purification on the serum, and collecting an antibody to obtain the anti-phospholipase A2 receptor polyclonal antibody, the amino acid sequence of the phospholipase A2 receptor protein comprises a sequence as shown in SEQ ID NO. 1. The specific antigen is designed and used for preparing the polyclonal antibody, the polyclonal antibody capable of specifically recognizing the phospholipase A2 receptor can be efficiently prepared, and the polyclonal antibody prepared by using the eukaryotic expression antigen is found to have the advantages that compared with the polyclonal antibody prepared by using the prokaryotic expression or polypeptide route source antigen, the polyclonal antibody prepared by using the eukaryotic expression antigen has the advantages that the specificity is high; and the anti-PLA2R related membranous nephropathy (called PLA2R MN for short) animal model can be more stably and efficiently constructed.

The invention belongs to the technical field of kidney histopathology and immunological evaluation, and particularly relates to a kidney pathology detection kit, a detection method and application, the detection kit comprises 37 rare metal element labeled monoclonal antibodies combined with antigens of in-situ tissue cells, and the detection method comprises the following steps: (1) collecting a sample to be detected, preparing a pre-dyed paraffin section; (2) mixing 37 monoclonal antibodies labeled by rare metal elements, and carrying out antibody staining on various antigen targets on the surfaces of cells in the in-situ tissue; (3) carrying out nucleus DNA staining on the stained tissue sample; and (4) detecting the stained tissue sample through an imaging mass spectrum flow system, and collecting original information data through laser spot firing. The method is an analysis method for fine grouping identification and relative quantification of structural cells, immune cells and pathological injury cells in the clinical nephropathy sample in-situ tissue. And auxiliary diagnosis information is provided for diagnosis, grading, treatment and prognosis detection of various clinical nephropathy.

The invention discloses a diabetic nephropathy risk assessment and prediction system based on platelet indexes, and particularly relates to the technical field of disease risk prediction, which comprises a platelet index acquisition module, a drug use data acquisition module, a drug intervention assessment module, an index correction module, a clustering analysis module and a diabetic nephropathy risk assessment module, the method comprises the following steps: acquiring platelet related detection indexes and historical medication data of a patient, calculating a drug intervention influence index and generating a correction factor, realizing platelet index reverse reduction correction by adopting a convolutional neural network model, determining a similar group in combination with clustering analysis, and dynamically evaluating the risk of diabetic nephropathy based on the average morbidity of the group. Personalized accurate prediction is realized; the platelet index correction accuracy is improved, individualized drug intervention elimination is achieved, the similar population clustering analysis precision is enhanced, diabetic nephropathy risk prediction is dynamically adjusted in combination with comprehensive scores, and the early screening and individualized intervention effects are improved.

The present invention provides a method for increasing glycemic control in a patient in need thereof, by administering tirzepatide, or a pharmaceutically acceptable salt thereof. The present invention provides a method for improving weight management in a patient in need thereof, by administering tirzepatide, or a pharmaceutically acceptable salt thereof. Further providing a method for treating a condition selected from atherosclerosis, chronic kidney disease, NAFLD, and NASH. Further provided is a method to prevent or induce remission of diabetes comprising administration of tirzepatide, or a pharmaceutically acceptable salt thereof. Further provided is a dosing regimen for increasing glycemic control, improving weight management, and / or treating dyslipidemia.

The invention relates to the technical field of medical health management, in particular to a chronic kidney disease and diabetes collaborative nutrition monitoring and early warning method and system.The method comprises the steps that multi-dimensional physiological indexes, nutrition intake and sleep data of a patient are obtained, and a dynamically-coupled metabolic state topological space is constructed; based on the space, constructing a dual-disease metabolism coupling matrix, analyzing stability characteristics of a metabolism state trajectory, identifying stable and unstable attractors, and calculating a multi-dimensional risk score; a sleep-metabolism synchronism risk prediction model is introduced, and a personalized early warning threshold value is dynamically adjusted; when the risk score exceeds a threshold value, early warning is triggered, and intervention suggestions are generated, the interactive influence of protein metabolism and glycometabolism is quantitatively described from the metabolic mechanism level, and the contradiction of chronic kidney disease and diabetic patients in nutrition management is solved; limitation of a static threshold is broken through, and dynamic risk assessment is realized; sleep factors are creatively integrated, and a new way for improving the metabolic state is provided.

The invention relates to a molecular model for auxiliary diagnosis of diabetic nephropathy based on proteomics detection of serum specimens of patients with diabetic nephropathy and non-diabetic nephropathy as well as a construction method and application of the molecular model, which can effectively screen out biomarkers for auxiliary diagnosis model construction and combine with important clinical variables to construct a clinical auxiliary diagnosis model. According to the technical scheme, the molecular model is formed by combining proteins MTTP, TNNI1 and ANGPTL8, the MTTP ratio of diabetic nephropathy patients to non-diabetic kidney disease patients is 8-12.5, the TNNI1 ratio is 7-15, and the ANGPTL8 ratio is 8-14, the protein composition in a sample is detected through a high-throughput mass spectrum means, and the molecular model has the advantages that the molecular model is simple in structure, convenient to operate and high in sensitivity, and the detection accuracy is high. The difference of a diabetic nephropathy patient group and a non-diabetic nephropathy group in the proteomics level is compared, the biomarker for auxiliary diagnosis model construction is screened out, and a new scheme is provided for auxiliary diagnosis of diabetic nephropathy.

The invention provides a hypertensive nephropathy prediction method based on multi-model fusion screening characteristics. An important feature set influencing the occurrence of hypertensive nephropathy is screened based on a multi-model fusion method, and a hypertensive nephropathy prediction model based on multi-model fusion is established by using the feature set. Early screening work for hypertension people is realized, so that the risk of hypertensive nephropathy can be found as early as possible, timely treatment is realized, and the prognosis of patients is improved.

Methods are disclosed for delivering a composition comprising an adeno-associated virus (AAV) to one or more kidney cell types in a subject with or without immunity against AAV, including locally delivering to the kidney of the subject an adeno-associated virus (AAV) comprising a genome and an AAV capsid protein via renal pelvic injection, wherein the renal pelvic injection comprises direct renal pelvic injection or retrograde transureteral renal pelvic injection. Methods are also disclosed for treating a kidney disorder in a subject with or without immunity against AAV, comprising locally delivering to the kidney of the subject via renal pelvic injection, including direct renal pelvic injection and retrograde transureteral renal pelvic injection, an adeno-associated virus (AAV) comprising a genome and an AAV capsid protein, wherein the genome encodes a therapeutic agent that treats the kidney disorder in the subject. The AAV can be AAVKP1, AAVKP2, AAVKP3, AAVDJ, AAV2G9, AAV2.7m8, AAV3, AAVLK03, or AAVShH10.

The invention provides a multi-modal kidney pathological picture processing method and device, electronic equipment and a medium. The method comprises the following steps: acquiring an immunofluorescence picture included in a to-be-processed multi-modal kidney pathological picture and a PAS staining pathological picture corresponding to the immunofluorescence picture; inputting the immunofluorescence pictures into a pre-trained first network model to perform nephropathy type classification to obtain nephropathy types; judging whether the nephropathy type output by a pre-trained first network model belongs to a preset nephropathy type or not; inputting a PAS staining pathological picture corresponding to the immunofluorescence picture into a pre-trained second network model for pathological structure identification when the immunofluorescence picture belongs to the preset nephropathy type, and outputting a label for the identified pathological structure; and adding an Oxford typing label to the to-be-processed multi-modal kidney pathological picture based on a label and a pathological structure output by a pre-trained second network model. According to the scheme, the nephropathy type can be automatically distinguished, the Oxford typing label is added, the processing speed is high, and the accuracy rate is high.

The invention discloses application of ADAM10 or ADAM17 serving as a target spot in preparation of a medicine for preventing / treating membranous nephropathy and application of an ADAM10 or ADAM17 inhibitor in preparation of the medicine for preventing / treating membranous nephropathy. The invention finds that ADAMs mediate the deposition process of immune complexes of autoantigens such as PLA2R1 of membranous nephropathy, and enzyme digestion of podocytes to transmembrane autoantigen proteins such as PLA2R can be inhibited by performing targeted intervention on the activity of ADAMs, especially the activity of ADAM10 and ADAM17, so that immune complexes deposited in glomerulus are reduced, the podocyte damage of membranous nephropathy is improved, and the therapeutic effect is achieved.

The present invention the invention concerns bifunctional compounds of Formula (I) A-T-L1-AG, Formula (II) A-L1-Con(L2-AG)n or Formula (III) Ak´-Th-L3 ii-AGj' wherein A is a protein that binds to the hinge region of galactose deficient IgA1 antibodies or a protein that binds to autoantibodies of galactose deficient IgA antibodies and AG is an asiaglycoprotein receptor binding moiety (ASGPR binding moiety). L1, Con and L2 are part of a linker between A and AG. The A has the ability to bind to antibodies that are a cause of IgA nephropathy and the asiaglycoprotein receptor binding moiety binds to hepatic cells thereby initiating endocytosis and removal of the antibodies that are a cause of IgA nephropathy from the blood stream.

The invention discloses a method for constructing a differential diagnosis model for lupus nephritis and membranous nephropathy, and belongs to the technical field of intelligent medical treatment. The modeling method comprises the following steps: S1, respectively collecting flow cytometry detection data of lupus nephritis patients and healthy control personnel; s2, performing data cleaning and conversion on the flow cytometry detection data, and converting non-numerical features into digits; carrying out implication on the missing value by adopting a k nearest neighbor algorithm from an implication packet; s3, random sampling is carried out on the cleaned and converted data set, and samples are divided into a training set and a verification set according to the proportion of 7: 3; s4, dividing a training subset and a test set from the training set, and iteratively selecting the types of cells incorporated into the constructed model as pDC, CD4T, effector CD4T, Th2, CD8T, CD38 + HLA-DR + CD8T, and CD38 + PD-1 + CD8T by adopting an RFE method, wherein the types of the cells incorporated into the constructed model are pDC, CD4T, effector CD4T, Th2, CD8T, CD38 + HLA-DR + CD8T and CD38 + PD-1 + CD8T; and S5, performing a classification task by adopting TabPFNClassifier, performing training from features selected from the training data set, then evaluating the performance of the model, performing model training by utilizing detection data, and performing evaluation to construct a lupus nephritis prediction model with high accuracy.

The compositions comprise at least two ingredients selected from the group consisting of fish oil, L-arginine, vitamin E, vitamin C, vitamin B3, vitamin B5, vitamin B6, vitamin B1, vitamin B2, folic acid, biotin, vitamin B12, and are formulated for the prevention and / or treatment of a disease or condition associated with muscle decline in a subject in need thereof. Preferably, the subject in need is an individual at risk of or having renal failure, renal dysfunction or / and nephropathy, such as chronic nephropathy, protein energy consumption, end-stage nephropathy, renal failure due to hospitalization in an intensive care unit, acute kidney injury, and the muscle decline is selected from the group consisting of muscle depletion, muscle loss due to renal failure or dysfunction, muscle decline associated with chronic kidney disease, muscle loss due to hospitalization in intensive care units during renal failure, metabolic acidosis during chronic kidney disease, protein energy depletion, or a combination thereof. The method enables the prevention and / or treatment of at least one outcome of a disease or condition associated with muscle decline in a subject at risk of or having renal failure, renal dysfunction or / and kidney disease. The composition and the method can be used to improve the level of at least one amino acid.

The invention discloses application of oligopeptide in preparation of a medicine for treating and / or preventing diabetic nephropathy. The oligopeptides comprise oligopeptides with the amino acid sequence of SEQ ID NO: 1: LNLYP and derivative sequences or conservative substitution variants of the oligopeptides. The oligopeptide can significantly improve renal function indexes of mice with diabetic nephropathy, such as UACR, serum creatinine, urea nitrogen and the like, enhance podocyte barrier integrity and inhibit accumulation of advanced glycosylation end products AGEs in kidney tissues, and provides a basis for development of novel drugs for treating diabetic nephropathy.

The invention belongs to the technical field of biology, and relates to a brevibacillus brevis YF02 strain for degrading creatinine, which can generate an enzyme for catalytically degrading creatinine. The invention also relates to a brevibacillus brevis YF02 preparation for degrading creatinine, and the brevibacillus brevis YF02 preparation contains bacterial cells and / or crude enzyme of the brevibacillus brevis YF02 strain. Research results show that the brevibacillus brevis YF02 cell for degrading creatinine and the enzyme produced by the brevibacillus brevis YF02 cell can completely degrade 500mg / L of creatinine within 48 hours and 24 hours respectively, and the brevibacillus brevis YF02 cell and the enzyme produced by the brevibacillus brevis YF02 cell have important application prospects in the aspects of reducing the creatinine level of human serum and preventing and treating nephropathy and corresponding complications.

The invention relates to a traditional Chinese medicine composition for treating spleen-kidney qi deficiency and stasis toxin obstruction type diabetic nephropathy, which can effectively solve the medication problem for treating spleen-kidney qi deficiency and stasis toxin obstruction type diabetic nephropathy. The traditional Chinese medicine composition is prepared from, by weight, 37-33 g of astragalus membranaceus, 27-33 g of centella asiatica, 18-22 g of ligusticum wallichii, 18-22 g of winged euonymus twig, 18-22 g of salvia miltiorrhiza and 14-16 g of prepared rehmannia root. The traditional Chinese medicine composition is prepared by removing impurities from the raw materials, washing, airing, smashing and evenly mixing. The components are simple, scientific and reasonable, are compatible according to the main and secondary relationship of monarch, minister, assistant and guide, are mutually correlated and compatible in function to play a role, and are combined to play the roles of clearing heat and promoting diuresis, detoxifying and activating blood, reinforcing qi and nourishing yin, and tonifying kidney and replenishing essence, so that the traditional Chinese medicine is effectively used for preparing the medicine for treating spleen-kidney qi deficiency and blood stasis toxin blocking type diabetic nephropathy, and is good in curative effect and free of toxic and side effects. The traditional Chinese medicine composition is a great innovation of medicines for treating spleen and kidney qi deficiency and stasis toxin blocking collateral type diabetic nephropathy, and has remarkable social and economic benefits.

Provided herein are pharmaceutical compositions comprising carotenoids, including liposomes that encapsulate carotenoids including ionizable carotenoids such as trans-crocetin. The provided compositions have uses in treating diseases, disorders and conditions associated with, but not limited to, infection, endotoxemia, inflammation, sepsis, ischemia, hypoxia, shock, stroke, lung injury, wound healing, traumatic injury, reperfusion injury, cardiovascular disease, kidney disease, liver disease, inflammatory disease, metabolic disease, pulmonary disorders, blood related disorders and hyperproliferative diseases such as cancer. Methods of making, delivering, and using the pharmaceutical compositions are also provided.

The invention provides a diabetic nephropathy early warning method, system, equipment and medium, and relates to the technical field of medical data analysis and prediction.The method comprises the steps that multiple urine samples of a user are collected, target urine protein detection is conducted, and multiple urine protein concentrations are obtained; each urine protein concentration is combined with a normal urine protein concentration set to be input into an abnormal data recognition tree, the number of layers of multiple recognition nodes is obtained, and the detection confidence coefficient is obtained through calculation; configuring an abnormal proportion according to the detection confidence coefficient, inputting a plurality of urine protein concentration combination normal urine protein concentration sets into an abnormal data identification tree, deleting urine protein concentrations divided into abnormal data in the abnormal proportion before, and obtaining screened urine protein concentrations; according to the screened urine protein concentration, an auxiliary early warning coefficient is obtained through calculation, and early warning is carried out. The technical problem of low early warning accuracy of diabetic nephropathy in the prior art is solved.

The invention discloses a biomarker for nephrotic syndrome, an analysis method and a kit, which can be effectively used for diagnosis of nephrotic syndrome and have high sensitivity and accurate and reliable results. The biomarker for nephrotic syndrome comprises the mRNA, the protein and the enzymatic activity level of the following substances: lactate dehydrogenase B.

The invention relates to an application of a compound DB07268 in preparation of a RAGAP1 inhibitor. Candidate compounds possibly interacting with RACGAP1 protein are screened out through large-scale virtual docking and CCK8 experiments and verified through SPR experiments, the compound DB07268 with the highest affinity with RACGAP1 is further screened out, and finally the acting effect of the compound DB07268 is verified through cell experiments and molecular experiments. Compared with the prior art, the invention discovers that DB07268 can be used as the RACGAP1 inhibitor for targeted therapy of RACGAP1 related diseases, such as various tumors, diabetic nephropathy, acute kidney injury, congenital heart disease, congenital erythropoiesis abnormality anemia, virus infectious diseases and the like.

The invention belongs to the technical field of traditional Chinese medicines, and provides novel medical application of Chinese tamarisk twigs. The Chinese tamarisk twigs can be used for preparing medicines for preventing and treating hyperuricemia, and medicines for treating uric acid kidney stone, tophus or uric acid nephropathy caused by hyperuricemia. The invention also provides a preparation method of the Chinese tamarisk twig extract, which adopts water or / and ethanol for extraction. The new medical application of the Chinese tamarisk twigs is provided, the medical value of the Chinese tamarisk twigs is expanded, and compared with an existing uric acid reducing medicine allopurinol, the obtained extract can reduce the uric acid level of hyperuricemia, can inhibit rising of renal function indexes such as serum creatinine and urea nitrogen induced by hyperuricemia, improves liver and kidney tissue injuries, and has the advantages of being free of toxic and side effects, safe and reliable. The traditional Chinese medicine composition has the effect of improving liver and kidney functions and has good safety.

The invention relates to a flavonoid active fraction of an Abelmoschi corolla, a preparation method and an application thereof, and belongs to the field of traditional Chinese pharmaceutics. A high-purity Abelmoschi corolla flavonoid active fraction is prepared, which is found to have better therapeutic activity for kidney disease, and especially have a significant therapeutic effect for diabetic kidney disease and lupus nephritis, or contrast-induced kidney injury and eye diseases. Meanwhile, the Abelmoschi corolla flavonoid active fraction described in the invention also has good safety.

The present invention belongs to the field of probiotic fermentation technology, and specifically relates to a fermented product of Bifidobacterium longum subsp. infantis, and a preparation method thereof, and applications thereof in improving testosterone levels and fertilization rates, improving chronic kidney disease, and combating fatigue. The Bifidobacterium longum subsp. infantis NKU FB3-14 composition of the present invention and a probiotic fermented product prepared using the Bifidobacterium longum subsp. infantis NKU FB3-14 composition as a raw material have bioactive substances that are different from the raw materials, thereby achieving the effects of improving testosterone levels and fertilization rates, improving chronic kidney disease, and combating fatigue.